SCHEMBL6489796

SCHEMBL6489796

CCOC(=O)CCCOc1ccc(NC(C)=O)c(NCc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
PABPC1 P11940 1/20 0.42
ALDH1A1 P00352 3/20 0.41
TP53 P04637 1/20 0.41
BRD4 O60885 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HPGD P15428 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CNR1 P21554 1/20 0.40
PDK2 Q15119 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
P2RY12 Q9H244 1/20 0.39
NPC1 O15118 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497406 0.93 BRD4 (0.41) MAPTMEN1KMT2ATDP1PABPC1
SCHEMBL6501452 0.88 IDO1 (0.41) MAPTMEN1KMT2ATDP1PABPC1
SCHEMBL6489966 0.87 BRD4 (0.37) TDP1PABPC1BRD4CNR1PDK2
SCHEMBL6487898 0.87 MAPT (0.42) MAPTMEN1KMT2ATDP1PABPC1
SCHEMBL6487724 0.84 HDAC1 (0.39) MAPTMEN1KMT2AALDH1A1HDAC1
SCHEMBL6829609 0.84 FFAR1 (0.40) MAPTKMT2ATDP1ALDH1A1BRD4
SCHEMBL6501801 0.82 HDAC1 (0.44) MAPTMEN1KMT2ATDP1PABPC1
SCHEMBL7064560 0.80 HRH3 (0.39) HDAC1HDAC8HDAC6HRH3NPC1
SCHEMBL6829611 0.80 FFAR4 (0.39) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL6301593 0.79 HDAC1 (0.54) MAPTMEN1KMT2AALDH1A1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAPT 3168/4885MEN1 1604/4885KMT2A 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.